Literature DB >> 11222574

In vitro activity of gemifloxacin against Helicobacter pylori.

H W Minehart, A F Chalker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222574     DOI: 10.1093/jac/47.3.360

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

Review 2.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.

Authors:  Jacques Tankovic; Christine Lascols; Quentin Sculo; Jean-Claude Petit; Claude-James Soussy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.

Authors:  Mohsen Masoodi; Mahshid Talebi-Taher; Khadijeh Tabatabaie; Siamak Khaleghi; Amir-Hossein Faghihi; Shahram Agah; Reyhaneh Asadi
Journal:  Middle East J Dig Dis       Date:  2015-04

5.  Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication.

Authors:  Fariborz Mansour-Ghanaei; Zahra Pedarpour; Afshin Shafaghi; Farahnaz Joukar
Journal:  Middle East J Dig Dis       Date:  2017-04

6.  High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.

Authors:  Laleh Mahmoudi; Shohreh Farshad; Mehrdad Seddigh; Paria Mahmoudi; Fardad Ejtehadi; Ramin Niknam
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.